These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 3137482)

  • 1. Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):281-3. PubMed ID: 3137482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, a major endogenous ligand substance in uremic serum, by high-performance liquid chromatography with ultraviolet detection.
    Mabuchi H; Nakahashi H
    J Chromatogr; 1987 Mar; 415(1):110-7. PubMed ID: 3584344
    [No Abstract]   [Full Text] [Related]  

  • 4. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
    Mabuchi H; Nakahashi H
    Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Underestimation of serum albumin by the bromcresol purple method and a major endogenous ligand in uremia.
    Mabuchi H; Nakahashi H
    Clin Chim Acta; 1987 Jul; 167(1):89-96. PubMed ID: 3665090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of renal transplantation on a major endogenous ligand retained in uremic serum.
    Mabuchi H; Nakahashi H; Hamajima T; Aikawa I; Oka T
    Am J Kidney Dis; 1989 Jan; 13(1):49-54. PubMed ID: 2643310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of an endogenous drug-binding inhibitor present in uremic serum.
    Mabuchi H; Nakahashi H
    Nephron; 1986; 44(4):277-81. PubMed ID: 3796769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
    Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
    Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding.
    Niwa T; Takeda N; Maeda K; Shibata M; Tatematsu A
    Clin Chim Acta; 1988 Apr; 173(2):127-38. PubMed ID: 3378354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of binding site of uremic toxins on human serum albumin.
    Sakai T; Takadate A; Otagiri M
    Biol Pharm Bull; 1995 Dec; 18(12):1755-61. PubMed ID: 8787801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major albumin-associated fluorescent substance in uremic serum.
    Mabuchi H
    Nephron; 1988; 48(4):328-9. PubMed ID: 3362283
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis.
    Niwa T; Asada H; Tsutsui S; Miyazaki T
    Am J Nephrol; 1995; 15(6):463-7. PubMed ID: 8546166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly sensitive simultaneous quantification of indoxyl sulfate and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high-performance liquid chromatography coupled with tandem mass spectrometry.
    Oda A; Suzuki Y; Sato B; Sato H; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Sep Sci; 2022 May; 45(10):1672-1682. PubMed ID: 35247297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and quantification of a protein-bound ligand in uremic serum.
    Takeda N; Niwa T; Tatematsu A; Suzuki M
    Clin Chem; 1987 May; 33(5):682-5. PubMed ID: 3568353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A major endogenous ligand substance involved in renal failure.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 49(4):277-80. PubMed ID: 3412543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced renal clearance of furancarboxylic acid, a major albumin-bound organic acid, in undialyzed uremic patients.
    Sato M; Koyama M; Miyazaki T; Niwa T
    Nephron; 1996; 74(2):419-21. PubMed ID: 8893167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of uremic toxins and nonesterified fatty acids on drug and thyroid hormone binding in serum.
    Lim CF; Stockigt JR
    Clin Chem; 1998 Nov; 44(11):2380-1. PubMed ID: 9799777
    [No Abstract]   [Full Text] [Related]  

  • 19. [Plasma concentrations of anionic uremic toxins in hemodialysis patients and their effects on protein binding of pravastatin].
    Ichimura Y; Takamatsu H; Ideuchi H; Oda M; Takeda K; Saitoh H
    Yakugaku Zasshi; 2015; 135(6):821-8. PubMed ID: 26028417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uremic toxins enhance statin-induced cytotoxicity in differentiated human rhabdomyosarcoma cells.
    Uchiyama H; Tsujimoto M; Shinmoto T; Ogino H; Oda T; Yoshida T; Furukubo T; Izumi S; Yamakawa T; Tachiki H; Minegaki T; Nishiguchi K
    Toxins (Basel); 2014 Sep; 6(9):2612-25. PubMed ID: 25192420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.